文献速递炎症性肠病消化道肿瘤与早癌

儿童炎症性肠病患者淋巴瘤风险低

Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2022-10-11

该研究利用2007至2018年IQVIA行政索赔数据库,分析接受治疗的儿童炎症性肠病(IBD)患者淋巴瘤风险。共纳入10,777例接受至少一种IBD治疗的患儿,随访28,292患者年,识别出5例淋巴瘤(发病率17.7/10万患者年,95%CI 6.5-39.2),其中4例曾使用硫嘌呤,无病例接受抗TNF单药治疗。结论认为接受治疗的儿童IBD患者淋巴瘤总体发病率低,抗TNF单药治疗相对安全。

要点

  • 接受治疗的儿童IBD患者淋巴瘤发病率为17.7/10万患者年(95%CI 6.5-39.2)。
  • 5例淋巴瘤中4例曾用硫嘌呤,无病例接受抗TNF单药治疗。
  • 抗TNF单药治疗儿童IBD的淋巴瘤风险未见增加。

核心结论

  • 在接受治疗的儿童IBD队列中,淋巴瘤总体发病率低。
  • 未观察到接受抗TNF单药治疗的患者发生淋巴瘤。
  • 这些发现支持抗TNF单药治疗儿童IBD的相对安全性。

研究设计与样本

  • 研究分析了2007至2018年IQVIA行政索赔数据库。
  • 通过ICD-9或ICD-10编码及药房索赔识别≤18岁的克罗恩病或溃疡性结肠炎患者。
  • 淋巴瘤病例由儿科肿瘤学家和胃肠病学家独立逐项索赔审查确认。
  • 共纳入10,777例接受至少一种IBD治疗的儿童IBD患者,中位年龄15岁(12-17),45%为女性,61%诊断为克罗恩病,随访28,292患者年。

主要发现

  • 接受治疗的患者中识别出5例淋巴瘤,发病率为17.7/10万患者年(95%CI 6.5-39.2)。
  • 5例淋巴瘤中4例在诊断前接受过硫嘌呤治疗,无病例接受抗TNF单药治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the effectiveness of immune-suppressing therapies in treating pediatric inflammatory bowel diseases (IBDs), concerns of lymphoma may limit their use. We used a large administrative claims database to evaluate the risk of lymphoma in pediatric IBD and conducted a case series analysis of medication exposure in children diagnosed with lymphoma. METHODS: We analyzed administrative claims from the 2007 to 2018 IQVIA database and identified pediatric (≤18 years) patients with Crohn's disease or ulcerative colitis using International Classification of Diseases, 9th or 10th Revision codes and pharmacy claims. Lymphoma cases were identified by diagnosis codes and confirmed by independent claim-by-claim review by a pediatric oncologist and gastroenterologist. We calculated incidence rates for lymphoma among patients with and without pharmacy claims for treatment followed by treatment description among those who developed lymphoma during follow-up. RESULTS: A total of 10,777 pediatric patients with IBD received ≥1 IBD therapy (median age 15 years [12-17], 45% female and 61% diagnosed with Crohn's disease) during 28,292 patient-years of follow-up. Among treated patients, 5 lymphoma cases were identified (incidence rate 17.7/100,000 patient-years; 95% confidence interval 6.5-39.2). Of these, 4 were treated with a thiopurine before lymphoma diagnosis, and none received anti-tumor necrosis factor-α (anti-TNF) monotherapy. DISCUSSION: The overall lymphoma incidence was low among our cohort of treated pediatric patients with IBD. We observed no cases of lymphoma among patients prescribed anti-TNF monotherapy. These findings reinforce the relative safety of anti-TNF monotherapy for the treatment of pediatric IBD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Egberg MD, Zhang X, Smitherman AB, et al. Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease. Am J Gastroenterol. 2022. PMID: 36219181. doi:10.14309/ajg.0000000000002053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。